Why the study?
The use of biomarkers in cardiorenal syndromes remains in its infancy, and further research is needed to establish their utility in routine clinical practice.
Can biomarkers improve the diagnosis, prognosis, and management of cardio renal syndromes?
Can biomarkers improve the diagnosis, prognosis, and management of cardio renal syndromes?
Emerging and established biomarkers offer potential for personalized diagnosis and management of cardio renal syndromes, though routine clinical application requires further validation.
Biomarkers may refine CRS diagnosis and risk stratification; leaves open optimal panels and prospective outcome trials before routine adoption.
Biomarkers have become an important tool in the diagnosis and management of cardio renal syndromes (CRS), a complex condition characterized by dysfunction in both the cardiovascular and renal systems. These biomarkers can help identify the presence and severity of CRS, predict its progression and outcomes, and facilitate personalized treatment options. Several biomarkers, including natriuretic peptides, troponins, and inflammatory markers, have been extensively studied in CRS and have shown promising results in improving diagnosis and prognosis. In addition, emerging biomarkers such as kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin offer potential for early detection and intervention of CRS. However, the use of biomarkers in CRS is still in its infancy, and further research is needed to establish their utility in routine clinical practice. This review highlights the role of biomarkers in the diagnosis, prognosis, and management of CRS and discusses their potential as valuable clinical tools for personalized medicine in the future.
No takes yet. Share an insight, caveat, or question.
Granado et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: